Elara Capital sees GLP-1 drugs as a major tailwind for India’s pharma sector, potentially becoming first-line therapy for diabetes and obesity. The brokerage recommends buying five stocks, accumulating four others, and selling one amid shifting metabolic treatment trends globally ahead.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets